# TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors

> **NCT03079440** · PHASE2 · COMPLETED · sponsor: **Asan Medical Center** · enrollment: 31 (actual)

## Conditions studied

- Neuroendocrine Tumors
- Neuroendocrine Carcinoma
- Temozolomide
- Capecitabine

## Interventions

- **DRUG:** TEMCAP

## Key facts

- **NCT ID:** NCT03079440
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-15
- **Primary completion:** 2020-11-15
- **Final completion:** 2022-11-15
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2022-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03079440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03079440, "TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03079440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*